DIAMEDICA THERAPEUTICS INC (DMAC) Institutional Buying Activity

Institutional investors tracked by InsiderSet increased exposure to DIAMEDICA THERAPEUTICS INC (DMAC) during the quarter ended March 31, 2026 through a combination of new purchases and expanded existing positions disclosed in SEC Form 13F filings.

The largest institutional buyer of DMAC during the latest reporting period was Renaissance Technologies LLC, which increased its reported DMAC position by approximately $546.761 based on quarter-end filing values. Several additional hedge funds and long-term asset managers also reported meaningful increases in DMAC exposure during the quarter.

Institutional buying activity can provide insight into investor conviction, sector allocation trends, and smart money positioning toward DIAMEDICA THERAPEUTICS INC (DMAC). InsiderSet tracks quarterly accumulation trends, new institutional positions, ownership increases, and estimated performance of newly disclosed holdings using SEC filing data and recent market prices.

The investors highlighted on this page collectively added approximately $1,205.911 in reported DMAC exposure during the latest filing period, reflecting continued institutional interest in DIAMEDICA THERAPEUTICS INC's growth initiatives and strategic positioning.

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q1 2023Renaissance Technologies LLCBuy30,88964,508$99
Q1 2021Renaissance Technologies LLCBuy39,700153,100$1,401
Q4 2020Renaissance Technologies LLCBuy17,400113,400$1,150
Q2 2020Renaissance Technologies LLCBuy78,851104,700$726
Q1 2020Renaissance Technologies LLCBuy25,84925,849$72

Frequently asked questions about DMAC activity

  • Which institutional owners are buying DMAC?

    Institutional owners buying DMAC include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in DMAC activity?

    "Buy" means an investor increased their reported position in DMAC compared to the prior reporting period. This reflects growing exposure to DIAMEDICA THERAPEUTICS INC (DMAC) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in DMAC increasing?

    Institutional interest in DMAC can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.